WuXi STA, a premier Contract Research, Development, and Manufacturing Organization (CRDMO), offers worldwide partners efficient, flexible, and high-quality integrated solutions for the manufacturing of active pharmaceutical ingredients and drug products to support preclinical to commercial uses. EwingCole and Genesis AEC provide full architectural and engineering design services for a new 458,000 SF of space that includes four buildings of OSD, LNP, formulation, filling, and packaging lines as well as warehousing, clinical research laboratories, administrative space, and its U.S. corporate headquarters. Phase I of this new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labeling, storage, and distribution services for clinical trial materials and commercial drug products. This new facility will bring roughly 500 new full-time jobs to Delaware. This project also includes the master planning of phases two and three, which will expand the drug product business and introduce drug substance manufacturing to complement the drug product manufacturing processes.